OSTEOARTHRITIS DRUG News, Sports, Shopping, Travel information

Osteoarthritis
Looking for Osteoarthritis? Search over 15,000 sites with one clicks. Your source for everything under the sun!
www.findstuff.com

Obesity Raises Risk Of Joint Replacement In People With Osteoarthritis - Eflux Media
we know for a fact that obese people have a high risk for high blood pressure, diabetes and several types of cancer. according to a new study carried out by flavia cicuttini of monash university in melbourne, australia, obesity also appears to worsen ...
www.efluxmedia.com

Hip Osteoarthritis Therapy No Better Than Placebo
friday, march 6 (healthday news) -- a single injection of hyaluronic acid is no more effective than a placebo in treating hip osteoarthritis (oa), a new french study finds.
news.yahoo.com

Hip Osteoarthritis Therapy No Better Than Placebo
fda-approved injection for knees less effective in deep joint areas, french study finds.
www.healthscout.com

Hip Osteoarthritis Therapy No Better Than Placebo - Healthscout
friday, march 6 (healthday news) -- a single injection of hyaluronic acid is no more effective than a placebo in treating hip osteoarthritis (oa), a new french study finds. hyaluronic acid (ha), a substance found in normal joint fluid, is used to ...
www.healthscout.com

Xoma Initiates Phase 2a Clinical Trial With Xoma 052 In Patients With ... - Phramalive.com
berkeley, calif., mar 4, 2009 (globenewswire via comtex news network) -- xoma ltd. (nasdaq:xoma) today announced the initiation of a phase 2a clinical study evaluating its product candidate xoma 052, a potent monoclonal antibody targeting interleukin ...
www.pharmalive.com

Fda Approves Genzyme's Synvisc-one For Osteoarthritis Of The Knee
genzyme corporation recently announced that the u.s. food and drug administration (fda) has granted marketing approval for synvisc-one(hylan g-f 20), a product intended for the relief of pain associated with osteoarthritis (oa) of the knee.
www.pharmaceuticalonline.com

Tissuegene Announces Regulatory Allowance To Initiate Phase Iia Study Of Tg-c In South Korea For Osteoarthritis Of The ...
tissuegene, inc. announced that its south korean licensing partner kolon life science, inc. (kls) has received regulatory allowance from the korea food and drug administration (kfda) to initiate a phase iia clinical trial of tissuegene-c (tg-c) in patients with severe osteoarthritis of the knee.
www.medicalnewstoday.com

Eu Approves Genzyme’s Pompe Disease Drug - Mass High Tech
genzyme corp. has received european approval for manufacturing myozyme, an anti-pompe disease drug. this week, genzyme (nasdaq: genz) announced that the european commission gave the thumbs-up for the production of myozyme at the 4,000-liter ...
www.masshightech.com

Otc Drugs Head Online - Dmnews.com
over-the-counter (otc) drugs may be some of the most visible products when it comes to tv and other mass-media ads. after all, who doesn't regularly see advertising for common pain relievers, allergy medicines or weight-loss aids? but while most otc ...
www.dmnews.com

Merck Withdraws Arthritis Drug Vioxx
in one of the largest prescription drug recalls in u.s. history, worldwide sales of the popular arthritis drug vioxx were halted today after new data pointed to an increased patient risk for heart attacks and stroke.
www.kfsm.com

Tissuegene Announces Regulatory Allowance To Initiate Phase Iia Study Of Tg-c In South Korea For Osteoarthritis Of The ...
tissuegene, inc. announced today that its south korean licensing partner kolon life science, inc. has received regulatory allowance from the korea food and drug administration to initiate a phase iia clinical trial of tissuegene-c in patients with severe osteoarthritis of the knee.
biz.yahoo.com

Tissuegene Announces Regulatory Allowance To Initiate Phase Iia Study ... - Medical News Today
tissuegene, inc. announced that its south korean licensing partner kolon life science, inc. (kls) has received regulatory allowance from the korea food and drug administration (kfda) to initiate a phase iia clinical trial of tissuegene-c (tg-c) in ...
www.medicalnewstoday.com

Synta Melanoma Drug Trial Halted, Drug Regulators Hand Genzyme Mixed ... - Xconomy
it was a bit of a rollercoaster for new england’s biotech firms this last week, with synta pharmaceuticals taking the worst dip. —clinical data (nasdaq: clda ) of newton, ma, has raised $50 million in a convertible debt financing aimed at ...
www.xconomy.com

How To Deal With Arthritis
osteoarthritis, the most common form, is a degenerative condition affecting the joints and the soft tissues around the joints _ the associated cartilage, ligaments, and tendons. the most commonly affected areas are the spine, the hands, and the shoulders, hips, and knees.
thechronicle-online.com

Genzyme's Synvisc-one Gets Us Fda Nod For Osteoarthritis Of The Knee
genzyme corporation announced that the us food and drug administration (fda) has granted marketing approval for synvisc-one (hylan g-f 20), a product intended for the relief of pain associated with osteoarthritis (oa) of the knee.
www.pharmabiz.com

Galapagos Nv (be) - Galapagos Confirms 2008 Financial Results ... - Phramalive.com
mechelen, belgium; 6 march 2009 - galapagos nv (euronext: glpg) presented financial results for the full year 2008 and progress in the execution of its strategy. galapagos achieved its financial goals in 2008. group revenues for the full year 2008 ...
www.pharmalive.com

Galapagos Confirms 2008 Financial Results, Foresees Strong Growth In ... - Asia Corporate News Network
* total revenues of ¤77.0 m (+17%) * r&d revenues of ¤31.5 m (+38%) driven by alliance milestones * biofocus dpi recurrent segment profit of ¤3.4 m * group net loss decreased 33% to ¤14.6 m * cash position of ¤27.3 m at year-end * continued ...
www.acnnewswire.com

Galapagos Confirms 2008 Financial Results, Foresees Strong Growth In 2009
click here to access the live audio webcast presentation at 10.00 cet, call number +32 2290 1791
biz.yahoo.com

Combinatorx Reports Financial Results For The Fourth Quarter And Year End 2008
combinatorx, incorporated (nasdaq: crxx) today reported financial results for the fourth quarter and year ended december 31, 2008.
www.centredaily.com

Anika Therapeutics Inc., Q4 2008 Earnings Conference Call - Seekingalpha.com
good day ladies and gentlemen and welcome to the fourth quarter 2008 anika therapeutics investors conference call. (operator instructions). i would now like to turn the call over to mr. kevin quinlan, anika’s chief financial officer. kevin w ...
seekingalpha.com